Non-alcoholic fatty liver disease and psoriasis - is there a shared proinflammatory network?
Journal
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
ISSN: 1610-0387
Titre abrégé: J Dtsch Dermatol Ges
Pays: Germany
ID NLM: 101164708
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
14
05
2020
accepted:
10
08
2020
pubmed:
27
3
2021
medline:
19
8
2021
entrez:
26
3
2021
Statut:
ppublish
Résumé
Psoriasis is an immune-mediated systemic inflammatory disease that is not limited to the skin but may be associated with arthritis, cardiovascular diseases, metabolic syndrome including diabetes and obesity and, as identified more recently, non-alcoholic fatty liver disease (NAFLD) that occurs in approximately 50 % of all patients with psoriasis. NAFLD is characterized by accumulation of fat in hepatocytes in the absence of excessive alcohol consumption. Over the last two decades, NAFLD has developed to the most common chronic liver disease with an estimated prevalence of 25 % in the Western population. NAFLD ranges from non-inflammatory or bland hepatic steatosis to inflammation of hepatic tissue (non-alcoholic steatohepatitis, NASH) and consecutive liver fibrosis. It is controversial whether the underlying systemic inflammation of psoriasis is contributing to development of NAFLD or if comorbid diseases such as obesity enhance NAFLD development. Recent findings indicate that cytokine-mediated inflammation through TNFα, interleukin (IL)-6 and IL-17 might be the common link between psoriasis and NAFLD. Considering the shared inflammatory pathways, IL-17 pharmacological blockade, which is already well-established for psoriasis, may be a promising strategy to treat both psoriasis and NAFLD. Therefore, early detection of NAFLD and a better understanding of its pathophysiology in the context of the systemic inflammation in psoriasis is important with regard to individualized treatment approaches.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
517-528Informations de copyright
© 2021 The Authors. Journal der Deutschen Dermatologischen Gesellschaft published by John Wiley & Sons Ltd on behalf of Deutsche Dermatologische Gesellschaft.
Références
Boehncke W-H, Schön MP. Psoriasis The Lancet 2015; 386: 983-94.
Hawro T, Zalewska A, Hawro M et al. Impact of psoriasis severity on family income and quality of life. J Eur Acad Dermatol Venereol 2015; 29: 438-43.
Gisondi P, Bellinato F, Girolomoni G, Albanesi C. Pathogenesis of chronic plaque psoriasis and its intersection with cardio-metabolic comorbidities. Front Pharmacol 2020; 11: 117.
Chalasani N, Younossi Z, Lavine JE et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67: 328-57.
Rau M, Geier A. Liver Disease, Nonalcoholic Fatty. In: Kuipers E: Encyclopedia of Gastroenterology. 2nd Edition. Oxford: Academic Press., Elsevier, 2020: 408-13.
Younossi Z, Tacke F, Arrese M et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology 2019; 69: 2672-82.
Estes C, Anstee QM, Arias-Loste MT et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol 2018; 69: 896-904.
Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol 2015; 62: S47-64.
Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci 2019; 20: 1475.
Bos JD, Hulsebosch HJ, Krieg SR et al. Immunocompetent cells in psoriasis. In situ immunophenotyping by monoclonal antibodies. Arch Dermatol Res 1983; 275: 181-9.
Zheng Y, Danilenko DM, Valdez P et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007; 445: 648-51.
Senra L, Stalder R, Alvarez Martinez D et al. Keratinocyte-derived IL-17E contributes to inflammation in psoriasis. J Invest Dermatol 2016; 136: 1970-80.
von Stebut E, Boehncke WH, Ghoreschi K et al. IL-17A in psoriasis and beyond: cardiovascular and metabolic implications. Front Immunol 2019; 10: 3096.
Wilson NJ, Boniface K, Chan JR et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007; 8: 950-7.
Grän F, Kerstan A, Serfling E et al. Current developments in the immunology of psoriasis. Yale J Biol Med 2020; 93: 97-110.
Alrefai H, Muhammad K, Rudolf R et al. NFATc1 supports imiquimod-induced skin inflammation by suppressing IL-10 synthesis in B cells. Nat Commun 2016; 7: 11724.
Hirsova P, Gores GJ. Death receptor-mediated cell death and proinflammatory signaling in nonalcoholic steatohepatitis. Cell Mol Gastroenterol Hepatol 2015; 1: 17-27.
Giles DA, Moreno-Fernandez ME, Divanovic S. IL-17 axis driven inflammation in non-alcoholic fatty liver disease progression. Curr Drug Targets 2015; 16: 1315-23.
Vonghia L, Michielsen P, Francque S. Immunological mechanisms in the pathophysiology of non-alcoholic steatohepatitis. Int J Mol Sci 2013; 14: 19867-90.
He B, Wu L, Xie W et al. The imbalance of Th17/Treg cells is involved in the progression of nonalcoholic fatty liver disease in mice. BMC Immunol 2017; 18: 33.
Rau M, Schilling AK, Meertens J et al. Progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis is marked by a higher frequency of Th17 cells in the liver and an increased Th17/resting regulatory T cell ratio in peripheral blood and in the liver. J Immunol 2016; 196: 97-105.
Tang Y, Bian Z, Zhao L et al. Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease. Clin Exp Immunol 2011; 166: 281-90.
Giles DA, Moreno-Fernandez ME, Stankiewicz TE et al. Regulation of Inflammation by IL-17A and IL-17F modulates non-alcoholic fatty liver disease pathogenesis. PLoS One 2016; 11: e0149783.
Balato N, Napolitano M, Ayala F et al. Nonalcoholic fatty liver disease, spleen and psoriasis: New aspects of low-grade chronic inflammation. World J Gastroenterol 2015; 21: 6892-7.
Tarantino G, Costantini S, Finelli C et al. Is serum Interleukin-17 associated with early atherosclerosis in obese patients? J Transl Med 2014; 12: 214.
Chehimi M, Vidal H, Eljaafari A. Pathogenic role of IL-17-producing immune cells in obesity, and related inflammatory diseases. J Clin Med 2017; 6(7): 68.
Weiß J, Rau M, Geier A. Non-alcoholic fatty liver disease: epidemiology, clinical course, investigation, and treatment. Dtsch Arztebl Int 2014; 111: 447-52.
Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2011; 33: 525-40.
Roeb E, Steffen HM, Bantel H et al. S2k Guideline non-alcoholic fatty liver disease. Z Gastroenterol 2015; 53: 668-723.
Roeb E, Geier A. Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments. Z Gastroenterol 2019; 57: 508-17.
Sandrin L, Fourquet B, Hasquenoph JM et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29: 1705-13.
Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatol 2006; 43(6): 1357-25.
Tandra S, Yeh MM, Brunt EM et al. Presence and significance of microvesicular steatosis in nonalcoholic fatty liver disease. J Hepatol 2011; 55: 654-9.
Kleiner DE, Makhlouf HR. Histology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in adults and children. Clin Liver Dis 2016; 20: 293-312.
Lonardo A, Loria P, Carulli N. Concurrent non-alcoholic steatohepatitis and psoriasis. Report of three cases from the POLI.ST.E.N.A. study. Dig Liver Dis 2001; 33: 86-7.
Abedini R, Salehi M, Lajevardi V, Beygi S. Patients with psoriasis are at a higher risk of developing nonalcoholic fatty liver disease. Clin Exp Dermatol 2015; 40: 722-7.
Madanagobalane S, Anandan S. The increased prevalence of non-alcoholic fatty liver disease in psoriatic patients: a study from South India. Australas J Dermatol 2012; 53: 190-7.
Awosika O, Eleryan MG, Rengifo-Pardo M et al. A case-control study to evaluate the prevalence of nonalcoholic fatty liver disease among patients with moderate-to-severe psoriasis. J Clin Aesthet Dermatol 2018; 11: 33-7.
Gisondi P, Targher G, Zoppini G, Girolomoni G. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009; 51: 758-64.
Narayanasamy K, Sanmarkan AD, Rajendran K et al. Relationship between psoriasis and non-alcoholic fatty liver disease. Prz Gastroenterol 2016; 11: 263-9.
Miele L, Vallone S, Cefalo C et al. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009; 51: 778-86.
van der Voort EA, Koehler EM, Dowlatshahi EA et al. Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: Results from a population-based study. J Am Acad Dermatol 2014; 70: 517-24.
van der Voort EA, Koehler EM, Nijsten T et al. Increased prevalence of advanced liver fibrosis in patients with psoriasis: a cross-sectional analysis from the Rotterdam study. Acta Derm Venereol 2016; 96: 213-7.
Ortolan A, Lorenzin M, Tadiotto G et al. Metabolic syndrome, non-alcoholic fatty liver disease and liver stiffness in psoriatic arthritis and psoriasis patients. Clin Rheumatol 2019; 38: 2843-50.
Magdaleno-Tapial J, Valenzuela-Oñate C, Ortiz-Salvador JM et al. Prevalence of non-alcoholic fatty liver and liver fibrosis in patients with moderate-severe psoriasis: A cross-sectional cohort study. Australas J Dermatol 2020; 61(2): 105-9.
Ogdie A, Grewal SK, Noe MH et al. Risk of incident liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis: a population-based study. J Invest Dermatol 2018; 138: 760-7.
Roberts KK, Cochet AE, Lamb PB et al. The prevalence of NAFLD and NASH among patients with psoriasis in a tertiary care dermatology and rheumatology clinic. Aliment Pharmacol Ther 2015; 41: 293-300.
Candia R, Ruiz A, Torres-Robles R et al. Risk of non-alcoholic fatty liver disease in patients with psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2015; 29: 656-62.
Finelli C, Tarantino G. What is the role of adiponectin in obesity related non-alcoholic fatty liver disease? World J Gastroenterol 2013; 19: 802-12.
Gerdes S, Rostami-Yazdi M, Mrowietz U. Adipokines and psoriasis. Exp Dermatol 2011; 20: 81-7.
Stojsavljevic´ S, Gomercˇic´ Palcˇic´ M, Virovic´ Jukic´ L et al. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20: 18070-91.
Campanati A, Ganzetti G, Giuliodori K et al. Serum levels of adipocytokines in psoriasis patients receiving tumor necrosis factor-α inhibitors: results of a retrospective analysis. Int J Dermatol 2015; 54: 839-45.
Coates LC, FitzGerald O, Helliwell PS, Paul C. Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same? Semin Arthritis Rheum 2016; 46: 291-304.
Mateen S, Zafar A, Moin S et al. Understanding the role of cytokines in the pathogenesis of rheumatoid arthritis. Clin Chim Acta 2016; 455: 161-71.
Prussick RB, Miele L. Nonalcoholic fatty liver disease in patients with psoriasis: a consequence of systemic inflammatory burden? Br J Dermatol 2018; 179: 16-29.
Nast A, Amelunxen L, Augustin M et al. S3-Leitlinie zur Therapie der Psoriasis vulgaris Update - Kurzfassung Teil 1 - Systemische Therapie. J Dtsch Dermatol Ges 2018; 16: 645-70.
Maybury CM, Jabbar-Lopez ZK, Wong T et al. Methotrexate and liver fibrosis in people with psoriasis: a systematic review of observational studies. Br J Dermatol 2014; 171: 17-29.
Kaushik SB, Lebwohl MG. Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol 2019; 80: 27-40.
Pongpit J, Porntharukchareon S, Kaewduang P et al. Liver stiffness measurement in psoriasis: do metabolic or disease factors play the important role? Biomed Res Int 2016; 2016: 7963972.
Paul C, Cather J, Gooderham M et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol 2015; 173: 1387-99.
Koca SS, Bahcecioglu IH, Poyrazoglu OK et al. The treatment with antibody of TNF-alpha reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet. Inflammation. 2008; 31: 91-8.
Campanati A, Ganzetti G, Di Sario A et al. The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis. J Gastroenterol 2013; 48: 839-46.
Seitz M, Reichenbach S, Möller B et al. Hepatoprotective effect of tumour necrosis factor alpha blockade in psoriatic arthritis: a cross-sectional study. Ann Rheum Dis 2010; 69: 1148-50.
Wong VW, Wong GL, Chan RS et al. Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease. J Hepatol 2018; 69: 1349-56.
Hohenester S, Christiansen S, Nagel J et al. Lifestyle intervention for morbid obesity: effects on liver steatosis, inflammation, and fibrosis. Am J Physiol Gastrointest Liver Physiol 2018; 315: G329-G38.
Gomes AL, Teijeiro A, Burén S et al. Metabolic inflammation-associated IL-17A causes non-alcoholic steatohepatitis and hepatocellular carcinoma. Cancer Cell 2016; 30: 161-75.
Harley IT, Stankiewicz TE, Giles DA et al. IL-17 signaling accelerates the progression of nonalcoholic fatty liver disease in mice. Hepatology 2014; 59: 1830-9.
Xu R, Tao A, Zhang S, Zhang M. Neutralization of interleukin-17 attenuates high fat diet-induced non-alcoholic fatty liver disease in mice. Acta Biochim Biophys Sin (Shanghai). 2013; 45: 726-33.
Mantovani A, Gisondi P, Lonardo A, Targher G. Relationship between non-alcoholic fatty liver disease and psoriasis: a novel hepato-dermal axis? Int J Mol Sci 2016; 17: 217.
Elmets CA, Leonardi CL, Davis DMR et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol 2019; 80: 1073-113.
Daudén E, Castañeda S, Suárez C et al. Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis. J Eur Acad Dermatol Venereol 2013; 27: 1387-404.
Nast A, Amelunxen L, Augustin M et al. S3-Leitlinie zur Therapie der Psoriasis vulgaris Update - Kurzfassung Teil 2 - Besondere Patientengruppen und spezielle Behandlungssituationen. J Dtsch Dermatol Ges 2018; 16: 806-14.